![Orexo, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f6e66e5-26fa-4ef7-9d45-5ca2ae233060.png)
Orexo
16,28 SEK -0,97%Vær den første som følger denne virksomhed
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
15,94 / 16,42
SEK
Markedsværdi
565,09 mio. SEK
Aktieomsætning
161,38 t SEK
Volumen
10 t
Seneste videoer
Finanskalender
Delårsrapport
14.11.2024
Årsrapport
06.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Novo A/S | 27,8 % | 27,8 % |
Avanza Pension | 6,6 % | 6,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
![Orexo, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f6e66e5-26fa-4ef7-9d45-5ca2ae233060.png)
Orexo Q2 2024 Interim Report
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orexo AB's sustainability work ranked among top 5% by EcoVadis
Orexo: invitation to presentation of the Q2 2024 Interim Report
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
![Orexo, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/432b12e0-7cb3-46cb-9747-d99a3fd5f1a5.png)
Orexo, Audiocast with teleconference, Q1, 2024
Orexo Q1 2024 Interim Report
Report from Orexo AB's annual general meeting, 26 April 2024
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
Orexo publishes the Annual and Sustainability Report for 2023
Correction: Notice of Annual General Meeting of Orexo
Notice of Annual General Meeting of Orexo
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
![Orexo, Investor Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1ee52405-d983-45fd-9ac1-a6c5bbe88a87.png)
Orexo, Investor Day, 2024
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
Orexo strengthens its sustainability work by establishing a social financing framework
Orexo and Sobi agree to advance feasibility study with AmorphOX
![Orexo, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/33a3ae77-8e95-4db6-92db-3d7c0117d7dd.png)